Tricaprilin

DRUG10 trials

Sponsors

Cerecin

Conditions

Age-Associated Memory ImpairmentAlzheimer DiseaseAlzheimer's DiseaseInfantile SpasmMigraineTaste Profile Assessments

Phase 1

Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production

CompletedNCT03551769

CerecinAlzheimer Disease

Start: 2018-08-05End: 2018-08-27Updated: 2019-05-29

Taste-masking Study for Tricaprilin in Sensory Panelists

CompletedNCT03628352

CerecinTaste Profile Assessments

Start: 2018-09-10End: 2019-08-22Updated: 2019-11-06

Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production

CompletedNCT03971123

CerecinAlzheimer Disease

Start: 2019-08-30End: 2020-05-26Updated: 2020-07-08

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

CompletedNCT04268953

CerecinAlzheimer Disease

Start: 2020-02-27End: 2020-05-01Updated: 2020-07-08

Tricaprilin Infantile Spasms Pilot Study

CompletedNCT04727970

CerecinInfantile Spasm

Start: 2021-11-01End: 2023-12-04Updated: 2024-09-19

Phase 2

Tricaprilin in Mild to Moderate Alzheimer's Disease

CompletedNCT00142805

CerecinAlzheimer's Disease

Start: 2004-11-04End: 2007-01-07Updated: 2020-09-21

Tricaprilin In Age-Associated Memory Impairment

CompletedNCT00355550

CerecinAge-Associated Memory Impairment

Start: 2006-07-31End: 2007-06-30Updated: 2020-09-18

Tricaprilin Phase 2 Pilot Study in Migraine

CompletedNCT04437199

CerecinMigraine

Start: 2020-12-17End: 2022-02-07Updated: 2024-02-08

Phase 3

A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension

WithdrawnNCT04187547

CerecinAlzheimer's Disease

Start: 2022-06-30End: 2024-02-28Updated: 2023-04-14

Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study

Not yet recruitingNCT05809908

CerecinAlzheimer Disease

Start: 2026-06-30End: 2029-01-31Target: 535Updated: 2025-11-25

Related Papers

Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study.

2024-07-221 citations

Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study.

2011-10-1244 citations

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

2009-08-10371 citations